COMPARISON OF STREPTOKINASE THERAPY SUCCESSFULNESS REGARDING DIABETIC STATUS AMONG ST-ELEVATION MYOCARDIAL INFARCTION (STEMI) PATIENTS

Introduction: Having diabetes is a major contributor to the likelihood of developing and experiencing complications from coronary artery disease. Acute myocardial infarction patients treated with intravenous streptokinase have a lower risk of death and improved survival. The goal of treating ST-elevation myocardial infarction (STEMI) with streptokinase therapy is to stop the infarction process and fix ischemia-metabolic imbalances in viable cells to keep them from dying. Objectives: The objectives of this study were to determine the overall successfulness of streptokinase therapy in all STEMI patients, compare streptokinase therapy successfulness regarding diabetic status among STEMI patients, and explain any related factors causing failure of streptokinase therapy. Method: This cross-sectional research was carried out at Khyber Teaching Hospital's cardiology department in Peshawar, Pakistan. 151 individuals hospitalized with STEMI who were candidates for streptokinase therapy were studied between June 1st, 2022 and September 30th, 2022 (4 months), in which a total of 76 patients had diabetes, whereas the other patients did not. Streptokinase was administered to every single patient. Then, streptokinase therapy outcomes were assessed. Results: Overall successfulness of streptokinase therapy was 86.8% in all STEMI patients. While streptokinase therapy successfulness regarding diabetic status among STEMI patients, streptokinase therapy was more successful in non-diabetic as compared to diabetic patients (97.3% vs. 76.3%) with a p value of